Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Yubo International Biotech Limited (YBGJ : OTC)
 
 • Company Description   
MAGNA-LAB INC. is a development stage company. Co. has developed and now markets and intends to produce the MAGNA-SLn, the first of Co.'s proposed series of anatomy specific MRI (Magnetic Resonance Imaging) products which are smaller and cost less to own, install and operate than present ``whole body`` MRI systems.

Number of Employees: 20

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 271 shares
Shares Outstanding: 118.18 (millions)
Market Capitalization: $8.30 (millions)
Beta: 6.84
52 Week High: $1.10
52 Week Low: $0.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.31% -30.53%
12 Week -75.89% -73.50%
Year To Date -83.16% -58.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Room 105 Building 5 31 Xishiku Avenue
-
Beijing,F4 10036
CHN
ph: 86-010-6615-5141
fax: 516-595-1159
None http://www.yubogroup.com
 
 • General Corporate Information   
Officers
Jun Wang - Chief Executive Officer; President and Director
Lina Liu - Chief Financial Officer; Treasurer and Director
Yang Wang - Director
Zhihui Bai - Director
Seymour Kessler - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 988366100
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 118.18
Most Recent Split Date: 3.00 (0.01:1)
Beta: 6.84
Market Capitalization: $8.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 10.40
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -96.71%
vs. Previous Quarter: -95.43%
ROE
03/31/22 - -
12/31/21 - -388.46
09/30/21 - -162.24
ROA
03/31/22 - -38.26
12/31/21 - -36.23
09/30/21 - -31.47
Current Ratio
03/31/22 - 0.27
12/31/21 - 0.38
09/30/21 - 0.53
Quick Ratio
03/31/22 - -
12/31/21 - 0.32
09/30/21 - 0.41
Operating Margin
03/31/22 - -210.80
12/31/21 - -123.89
09/30/21 - -
Net Margin
03/31/22 - -210.80
12/31/21 - -123.89
09/30/21 - -
Pre-Tax Margin
03/31/22 - -210.80
12/31/21 - -123.96
09/30/21 - -125.66
Book Value
03/31/22 - -0.01
12/31/21 - 0.00
09/30/21 - 0.00
Inventory Turnover
03/31/22 - 1.43
12/31/21 - 2.34
09/30/21 - 1.98
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©